Recent advances in the treatment of multiple sclerosis represent the most significant therapeutic success in neurology since the introduction of L-dopa for Parkinsonism 40 years ago. Traditional clinical trials in MS have required large numbers of subjects for a period of six months or longer. However, due to the intense competition for MS subjects, as well as technological advances and understanding of imaging techniques, MS clinical trial design is evolving. Efficient and focused subject recruitment approaches, combined with state-of-the-art trial design, are required to assess the large number of potential therapeutics in the clinical development pipeline.

In this audio conference, Dr. Peroutka discusses recent successes in MS treatment and provides attendees with practical knowledge concerning CNS clinical research, the competitive MS landscape and the analytic approach to MS subject recruitment. He also shares his insights on the conduct of MS studies, including how to leverage global experience locally.

This audio conference covers:

• Recent successes in MS treatment
• The competitive MS landscape
• An analytic approach to MS subject recruitment
• How to leverage global experience locally
• An overview of CNS clinical research

About the speaker:

Stephen Peroutka, MD, PhD, is Vice President, Neurosciences, Scientific Affairs at PRA International. He is a neurologist and pharmacologist whose research and professional experience in neurosciences spans 30 years. In 1990, he began his career in the industry by joining Genentech, where he established the Department of Neuroscience and became its first director. Subsequently, he founded Spectra Biomedical, a company focused on migraine genetics. After Spectra Biomedical was acquired by GSK he has acted as an independent consultant to the pharmaceutical and biotechnology industries for several years.

Dr. Peroutka received his MD and PhD from the Johns Hopkins University School of Medicine. After completing an internship at Stanford and a residency at Johns Hopkins Hospital, he was an Assistant Professor of Neurology and Pharmacology at Stanford, followed by Chief, Neurology Service at the Palo Alto VA Hospital.

Who should attend?

• Chief Medical Officers
• VPs of Clinical Development
• VPs/Directors of Clinical Operations
• Directors/Managers of Clinical Development

*Please note: Each registration covers one line connected to the audio conference. Attendees dialing from separate locations are required to have separate registrations.